Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11151588 | 0.79 | TAAR1 (0.57) | TAAR1IDO1ACHEMAOBALDH1A1 | |
| SCHEMBL5253754 | 0.78 | TAAR1 (0.50) | TAAR1IDO1ACHEMAOBALDH1A1 | |
| SCHEMBL559361 | 0.78 | TAAR1 (0.55) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL1004333 | 0.77 | ALDH1A1 (0.39) | ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL613603 | 0.76 | TAAR1 (0.52) | TAAR1IDO1MAOBALDH1A1MAPK1 | |
| SCHEMBL5247988 | 0.75 | GRIN2D (0.40) | TAAR1MEN1KMT2A | |
| SCHEMBL30589449 | 0.75 | — | — | |
| SCHEMBL177507 | 0.75 | — | — | |
| SCHEMBL1001014 | 0.74 | PNMT (0.54) | TAAR1IDO1MAOB | |
| SCHEMBL1538033 | 0.74 | TAAR1 (0.50) | TAAR1IDO1MAOBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| US-20260132149-A1 | Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith | BEONE MEDICINES I GMBH (CH) | 2026-05-14 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250298309-A1 | SEMICONDUCTOR PHOTORESIST COMPOSITIONS AND METHODS OF FORMING PATTERNS USING THE COMPOSITION | SAMSUNG SDI CO., LTD. (KR) | 2025-09-25 | — | — | US | disclosed |
| US-9670244-B2 | Oxysterol compounds and the hedgehog pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-06 | — | — | US | disclosed |
| EP-1993558-B1 | OXYSTEROL COMPOUNDS AND THE HEDGEHOG PATHWAY | UNIV CALIFORNIA (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8022052-B2 | Inhibition of PPAR gamma expression by specific osteogenic oxysterols | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-20 | — | — | US | disclosed |
| WO-2011006087-A1 | INHIBITION OF PPAR GAMMA EXPRESSION IN PREADIPOCYTE CELLS BY OXYSTEROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100105645-A1 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100034781-A1 | Oxysterol Compounds and the Hedgehog Pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-11 | — | — | US | disclosed |
| US-6861566-B2 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1369405-A1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-0309766-B1 | N-acylamino acid derivatives and their use | BANYU PHARMA CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5506356-A | RENIN INHIBITORS; HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| US-5481036-A | RENIN INHIBITORS, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| US-5319082-A | N-acylamino acid derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| US-5240924-A | Dipeptide hypotensives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105645-A1 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS | PPARA, PPARG, EBP | TAAR1 2834/4885IDO1 4026/4885ACHE 4835/4885 |
| US-20100034781-A1 | Oxysterol Compounds and the Hedgehog Pathway | SHH, SMO, NR1H3 | TAAR1 2058/4885IDO1 4108/4885ACHE 2327/4885 |
| US-20260132149-A1 | Bridged Cyclic 5-Amino-6,8-Dihydro-1H-Furo[3,4-D]Pyrrolo[3,2-B]Pyridine-2-Carboxamide Compounds, Compositions Thereof, and Methods of Treatment Therewith | MECP2, PRMT5, DNMT1 | TAAR1 3730/4885IDO1 3024/4885ACHE 4628/4885 |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | CYP1B1, CBR1, CYP1A1 | TAAR1 77/4885IDO1 114/4885ACHE 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.